Related Experiment Video

Updated: Oct 7, 2025

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.9K

Avelumab in locally advanced or metastatic urothelial carcinoma

Francesca Jackson-Spence1, Bernadett Szabados1, Charlotte Toms2

  • 1Barts Cancer Institute, Queen Mary University of London, London, UK.

Expert Review of Anticancer Therapy
|January 11, 2022
PubMed
Abstract

Insights

Maintenance avelumab after chemotherapy is a new standard of care for advanced urothelial carcinoma (UC). This programmed death ligand-1 (PD-L1) inhibitor offers a promising treatment option for patients with metastatic UC.

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Advanced or metastatic urothelial carcinoma (UC) has poor patient outcomes.
  • Targeting the programmed death ligand-1 (PD-(L)1) immune checkpoint pathway is a key strategy in UC treatment.
  • Avelumab, a PD-L1 inhibitor, restores cytotoxic, antitumor T cell response.

Purpose of the Study:

  • To review the clinical evidence for avelumab in urothelial carcinoma (UC).
  • To highlight the role of avelumab as a maintenance therapy following chemotherapy.

Main Methods:

  • Review of clinical evidence for avelumab in UC.
  • Focus on the maintenance approach after platinum-based chemotherapy.

Main Results:

  • The JAVELIN bladder 100 trial established a new standard of care.
  • Maintenance avelumab following platinum-based chemotherapy is now standard for advanced or metastatic UC.

Conclusions:

  • Immune checkpoint inhibitors show promise for metastatic UC but require optimization.
  • First-line maintenance avelumab presents an attractive treatment option for patients.
  • Future research is expected to significantly advance treatment strategies for UC.
Keywords:
Avelumabbiomarkergenitourinary cancerimmune checkpoint inhibitorsimmunotherapysystemic therapyurothelial carcinoma

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
712
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K